<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929396</url>
  </required_header>
  <id_info>
    <org_study_id>THYB-02</org_study_id>
    <nct_id>NCT00929396</nct_id>
  </id_info>
  <brief_title>A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers</brief_title>
  <acronym>THYB-02</acronym>
  <official_title>A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)Administered in PPD Positive Volunteers at 0 and 2 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Statens Serum Institut</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile of an adjuvanted TB subunit
      vaccine administered at 0 and 2 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical examination. Local adverse events.Systemic adverse events. Laboratory safety tests including urine safety tests.</measure>
    <time_frame>From first vaccination until 8 months after the first vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection by ELISPOT of IFNgamma spot-forming cells in PBMCs. Detection by ELISA of IFNgamma production in supernatants of PBMC. Detection by ELISA of IgG antibodies in serum/plasma. Detection by Elisa of TNFalfa and IFNgamma in serum</measure>
    <time_frame>From first vaccination until 8 months after first vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Latent TB infection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The latent TB group will receive two injections of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG vaccinated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The BCG vaccinated group will receive two vaccinations of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)</intervention_name>
    <description>o,5 mL suspension for injection x 2 with 2 months interval</description>
    <arm_group_label>BCG vaccinated group</arm_group_label>
    <other_name>Antigen H1 + adjuvant IC31</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)</intervention_name>
    <description>o,5 mL suspension for injection x 2 with 2 months interval</description>
    <arm_group_label>Latent TB infection group</arm_group_label>
    <other_name>Antigen H1 + adjuvant IC31</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female between 18 and 55 years old

          -  BCG group: Known to be BCG-vaccinated over 2 years before, PPD positive (range 6-15 mm
             or any documented value between 6-15 mm on medical file in the past), with no active,
             chronic or past TB disease as confirmed by chest X ray, negative QuantiFERON-TB Gold
             In Tube test and negative 6-day lymphocyte tests.

          -  Infection group: Known to be treated for latent TB, PPDpositive (equal or over 10 mm
             or documented equal or over 10 mm positive on medical file in the past), previously TB
             infected but with no active disease confirmed by chest X ray, may have received
             chemoprophylaxis but with no TB treatment/chemoprophylaxis within the preceding 2
             years, positive QuantiFERON-TB Gold In Tube test and/or positive 6-day lymphocyte
             test.

          -  Healthy based on medical examination/history at the inclusion

          -  Signed informed consent

          -  Prepared to grant authorized persons access to the medical records

          -  The volunteer is likely to comply with instructions

        Exclusion Criteria:

          -  Granulomatous disease (by chest X-ray)

          -  Vaccinated with live vaccine 3 months before first vaccination

          -  Administration of immune modulating drugs (steroids, immunosuppressive drugs or
             immunoglobulins) 3 months before the first vaccination

          -  HBV, HCV or HIV sero-positive

          -  Participation in other clinical trials

          -  Known hypersensitivity to any of the vaccine components

          -  Laboratory parameters outside of normal range judged by PI to be clinically relevant

          -  Pregnant women/planned pregnancy and/or breastfeeding within the trial period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaap van Dissel, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <state>RC Leiden</state>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2009</study_first_submitted>
  <study_first_submitted_qc>June 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2009</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Ag85B</keyword>
  <keyword>ESAT-6</keyword>
  <keyword>IC31</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

